STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

NAC

Also known as

N-acetylcysteine · N-acetyl-L-cysteine · N-acetyl cysteine · Acetylcysteine · Acetadote (IV brand discussions) · Mucomyst (historical mucolytic / oral antidote brand talk) · NALC · GlyNAC (glycine + NAC stack name) · N-AcCys

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Some talk Systemic Oral; clinical IV / inhaled Antioxidant & detox discussion

Systemic oral/IV cysteine donor; glutathione and system xc− talk. Inhaled NAC is more airway-local; topical use is local.

What people say NAC is acetylated cysteine. Supplement discussions focus on mucus, glutathione, hangovers and compulsive urges or cravings; its clinical roles include mucus treatment and acetaminophen-overdose care.Consumer capsules are not hospital antidote protocols, and mental-health findings are mixed. Doses people talk about
Everyday oral supplement talk~600–1,200 mg/day orally

Capsule/tablet accounts include 600 mg once daily or 600 mg twice daily; this is a community band, not an antidote regimen.

Respiratory discussion600–1,200 mg/day orally

Higher-dose respiratory reports often describe 600 mg twice daily over months. Trial outcomes are mixed; this row does not describe nebulized or IV products.

OCD/BFRB trial-style discussion~1,200–3,000 mg/day orally

OCD reports often describe divided twice-/three-times-daily exposure over 10–16 weeks; BFRB study schedules differ. Findings are mixed, not a self-treatment schedule.

Reported ranges, not dose recommendations. Study endpoints and results differ; hospital antidote and GlyNAC research loads remain separate contexts in the full notes.

Half-life & effect duration

Half-life in the body
  • Total NAC · oral studyAbout 6.3 hours
  • Total NAC · IV studyAbout 5.6 hours
  • Other oral tablet studyAbout 15–19 hours
  • Separate end-stage kidney-disease studyOver 50 hours
Felt duration people report
  • One relief accountFaded after about 8 hours
  • Other accountsNo noticeable benefit after 5 weeks, or anxiety lasting hours
Timing context & sources
How it may feel Reports include sulfur smell or taste, stomach upset and easier mucus clearance. Mental-effect accounts range from quieter intrusive thoughts to no change, anxiety or emotional flattening; other treatments and stacks complicate attribution.
Cycles people discuss Discussion includes ongoing daily oral use, months-long respiratory or fertility routines, and psychiatric/BFRB study blocks of roughly 8–24 weeks. Illness/event pulses and breaks for GI tolerance, cost or reassessment also appear; there is no shared washout calendar. Timing Oral blood peaks are reported around 1–2 hours. Posts describe splitting larger daily totals and disagree on empty-stomach versus food use; these practices and the plasma clock do not establish how long mucus or mental effects last. Stacks GlyNAC pairs NAC with glycine. Liver/hangover stacks add agents such as milk thistle, TUDCA or electrolytes; psychiatric accounts may also involve medicines or behavioral therapy, making NAC-only effects hard to separate. Watch for GI (most common oral): Nausea, vomiting, diarrhea, heartburn, bloating, gas, abdominal pain — dose-dependent; worse multi-gram or empty stomach.
Related
GlycineGlutathioneALATUDCA

Tap a line for the full notes and source context.

Timing context & sources

Half-life in the body

About 6 hours for total NAC in one oral study; another tablet study reported a longer terminal phase of about 15–19 hours.

These studies measure blood NAC differently. The longer figures are single-dose results, not proof that repeat dosing lengthens half-life.

Distinct assays and study designs are not interchangeable. These measurements do not establish duration of mucus, glutathione or mental-health effects.

  • Olsson et al.: reduced and total NAC pharmacokinetics (opens in a new tab)1988 abstract: six healthy volunteers, oral/IV crossover; total oral NAC 6.25 hours, total IV 5.58 hours, reduced IV 1.95 hours.Abstract only. Total and reduced analytes differ; pharmaceutical R&D author affiliation. The reduced IV value is not oral clearance.
  • Papi et al.: single and repeated oral NAC tablets (opens in a new tab)Original paper, DOI 10.1007/s12325-020-01542-4; PDF pages 3–4 Methods and page 7 Table 2, single-dose Days 1–2 columns.Manufacturer-funded Fluimucil tablet study in 30 healthy adults. Baseline-corrected assay reduces disulfides; two participants excluded from terminal estimates. This is not evidence that repeat dosing caused the longer half-life.

Felt duration people report

One account describes relief fading after about 8 hours; another reports no noticeable benefit after five weeks. Anxiety lasting hours is also reported.

The relief account followed ketamine/TMS, and the anxiety account involved early sobriety. Neither isolates NAC's effects.

Selected experiences, not typical effect length or evidence that NAC treats a psychiatric condition. No safe-use interval can be inferred.

Other context in this card

  • NAC sparse-use thread: clarity, emotional flattening and disagreement (opens in a new tab)Cold4Yu original post: less brain fog/noise, then anhedonia/depression after several consecutive days; deleted top-level account: anhedonia within weeks; Crayonlover123: anxiety and improvement within two days of stopping; redcyanmagenta and elesde replies: disagreement about perceived prevalence and personal experience.Public thread content inspected, not search snippets; some identities are deleted and replies collapsed. Diagnoses, product identity, co-use and causation are uncontrolled. Regimen-seeking context includes unsafe/unverified advice; no claimed incidence, biochemical explanation, alcohol/MDMA advice or preventive cycling protocol is adopted.

What people say 23

  • Liver-support / hangover stacks: Daily oral NAC in detox and post-alcohol stacks — mostly subjective endpoints; hangover-cure marketing was part of FDA warning-letter history for unapproved disease claims. forum
  • Hangover timing lore: Common forum pattern is ~600–1,200 mg on empty stomach 1–2 hours before drinking and/or next morning — confounded by hydration, food, sleep, and other stack ingredients. forum
  • Nail-biting / other BFRBs: Community adjunct after Grant-style BFRB signals; formal dosing often borrowed from 600–2,400 mg/day (sometimes up to ~3,000–3,600 mg talk) BFRB bands. forum
  • Athletic / training talk: High-dose antioxidant use debated — some users report less DOMS or illness; others and sports-science threads warn chronic high antioxidants may blunt training adaptations. forum
  • Stack note: Often credited inside GlyNAC or multi-antioxidant / fertility / liver stacks — hard to isolate NAC alone. forum
  • Acetaminophen overdose (clinical gold standard): High-dose weight-based oral or IV NAC is standard emergency care to replenish hepatic GSH and limit APAP hepatotoxicity — not consumer capsule math. trial
  • Mucolytic / airway clearance: Oral or inhaled acetylcysteine thins viscous mucus by breaking disulfide bridges; users and clinicians report easier productive cough and less “stuck” sputum. trial
  • COPD / chronic bronchitis culture: Oral ~600–1,200 mg/day (often 600 mg BID as “high dose”) discussed for fewer exacerbations and better expectoration; some older meta-talk favored ≥1,200 mg/day for antioxidant/GSH effect when 600 mg once daily did not raise GSH. trial
  • COPD evidence honesty: Not all modern reviews agree — some meta-analyses find little or no reduction in exacerbations or lung-function gain across 600–1,800+ mg bands; community still treats high-dose respiratory use as common practice in several markets. trial
  • Bronchiectasis observational talk: Multi-center observational work compared chronic 600 mg/day vs 1,200 mg/day over multi-year follow-up; higher-dose arm discussions often favor 1,200 mg for clinical outcomes in secondary summaries. trial
  • Glutathione donor: Practical oral cysteine source when plain oral GSH absorption is debated; community often prefers NAC or GlyNAC over cheap oral GSH tablets; some comparative work favored sublingual GSH over oral GSH and NAC for plasma GSH markers — still contested. trial
  • OCD / compulsion adjunct: RCTs commonly ~1,200–3,000 mg/day (often ~2,400–3,000 mg split BID/TID) as SSRI adjunct over ~10–16 weeks (some protocols to 24 weeks with optional step-up); results mixed positive and null across trials and meta-analyses. trial
  • Trichotillomania (hair-pulling): Adult double-blind RCT signal at ~1,200–2,400 mg/day (Grant-style); pediatric RCT was null vs placebo — community repeatedly notes adult vs child split. trial
  • Skin-picking (excoriation disorder): Adult RCT dosing ~1,200–3,000 mg/day (Grant et al. 12-week trial; ~47% improved vs ~19% placebo in commonly cited summaries); open-label work up to ~3,000 mg/day also discussed. trial
  • Cannabis use disorder — adolescents: Positive signal at 2,400 mg/day (1,200 mg BID) for ~8 weeks (Gray et al. style adolescent RCT) with higher rates of negative urine cannabinoid tests vs placebo + contingency management. trial
  • Cannabis use disorder — adults: Large CTN-0053 adult RCT at same 2,400 mg/day (1,200 mg BID) × 12 weeks was null for abstinence vs placebo + contingency management — age-dependent response lore is widespread. trial
  • Other craving / SUD pilots: Nicotine, cocaine, alcohol, gambling — multi-gram/day pilots and craving meta-analyses; promising but not uniform across substances or ages. Some tobacco+cannabis protocols discuss up to ~3,600 mg/day in trial registries. trial
  • Male fertility: ~600 mg/day oral for ~3 months (sometimes ~26 weeks) in idiopathic infertility trials/meta-analyses associated with better concentration, motility, morphology, and volume; hormone changes inconsistent across studies. trial
  • Fertility + selenium combo: Safarinejad-style RCT arms used 200 mcg selenium, 600 mg NAC, both, or placebo for 26 weeks — both singles improved semen parameters with additive benefit when combined. trial
  • Schizophrenia negative-symptom adjunct: Berk-line work often ~2,000 mg/day over ~24 weeks with signal on negative/total PANSS and some working-memory talk; meta-analyses suggest benefits may need longer exposure (≥~24 weeks) more than short 8-week windows. trial
  • Clozapine-resistant caveat: A 52-week RCT of ~2 g/day NAC in clozapine-stabilized residual-symptom patients did not support efficacy for negative symptoms — community notes population-specific nulls. trial
  • Autism irritability adjunct: Meta-analysis of pediatric/adolescent RCTs (doses spanning roughly ~500–4,200 mg/day across trials, often multi-week) reported ABC total / irritability / hyperactivity improvements; the largest/longest trial at ~500 mg/day was null. Underdosing is a community explanation, not an established cause of the null result. trial
  • Bipolar / depression adjacency: Mixed adjunct signals; some mania/depression pilot dosing in youth cited ~1,800 mg (children) and ~2,700 mg (adolescents) titrated over 2–3 weeks; not a first-line mood stabilizer substitute. trial

Doses people talk about 29

  • Consumer / wellness oral band: Often ~600–1,200 mg/day (e.g. 600 mg once or 600 mg BID). forum
  • Classic BFRB ramp (patient-education style): 600 mg daily × ~1–2 weeks + multivitamin/minerals + ~500 mg vitamin C → 600 mg BID if tolerated → 600 mg TID if needed, waiting ~2–3 weeks per step. forum
  • Clinic-style BFRB start: Often 600 mg BID (1,200 mg/day) then increase by 600 mg every 1–2 weeks toward 1,800–3,000 mg/day as tolerated. forum
  • Pediatric BFRB dosing talk (non-standard): Some pediatric practice notes discuss ~600–2,400 mg for kids over ~45 lb; weight-based suggestions around ~60 mg/kg/day appear in secondary write-ups without a single settled pediatric standard. forum
  • GlyNAC body-weight math (community): For a ~70 kg adult at 100 mg/kg each ≈ ~7 g glycine + ~7 g NAC/day — multi-gram powder territory; some guides suggest starting ~half dose (~50 mg/kg each) for the first week. forum
  • Community GlyNAC start talk: Many start ~600 mg glycine + 600 mg NAC daily and titrate; not the same as full weight-based study loads. forum
  • Split dosing: BID or TID patterns are discussed once daily totals exceed ~1,200 mg, with GI tolerance and multi-hour plasma half-life cited as rationales. This is community practice, not a validated interval derived from NAC blood levels or felt duration. forum
  • Empty stomach vs food: Empty stomach often preferred for absorption lore and pre-alcohol stacks; with meals preferred when nausea hits — practice not fully standardized. Protein-heavy meals sometimes discouraged in forum absorption talk. forum
  • Uncertainty: Capsule label accuracy, form (effervescent vs plain vs powder), food timing, brand sulfur odor, and Amazon-era reformulations vary; copy-pasting trial grams without clinical oversight is a recurring caution. forum
  • Examine-style research span: Oral studies cited from roughly ~300 mg up to ~6,000+ mg/day in edge research contexts; typical supplement talk clusters ~600–1,800 mg/day; multi-gram psych/SUD arms sit higher. trial
  • Well-tolerated oral talk: Secondary sources often state oral doses up to ~3,000 mg/day are generally well tolerated in study contexts — GI still the limiter. trial
  • Respiratory / COPD culture: ~600 mg/day licensed-style chronic use in some markets; “high-dose” respiratory talk often 1,200 mg/day (600 mg BID); some COPD literature spans 400–3,600 mg/day across trials of months to years. trial
  • Bronchiectasis observational split: 600 mg/day vs 1,200 mg/day chronic comparison appears in multi-center observational work — higher dose discussed as more effective in secondary write-ups. trial
  • OCD pediatric/adolescent talk: Target bands often ~2,400–2,700 mg/day in divided doses in specialty write-ups; pediatric evidence base is thinner than adult. trial
  • BFRB / trichotillomania: Often 1,200–2,400 mg/day; Grant-style adult hair-pulling used 1,200–2,400 mg; clinician commentary (Grant/BFRB foundation-style) often starts at 1,200 rather than 600 because lower dose “helps very few,” with occasional speculation up to ~3,600 mg/day unstudied in controlled BFRB trials. trial
  • Addiction / craving trials: Often 2,400 mg/day (1,200 mg BID) for cannabis and several SUD protocols; other arms span ~1,200–3,000+ mg/day; some tobacco/cannabis registry protocols list ~3,600 mg/day. trial
  • Schizophrenia adjunct: Commonly ~2,000 mg/day (often split) for multi-month blocks; trial ranges in reviews span roughly ~1,000–3,600 mg/day. trial
  • Male fertility trials: Frequently 600 mg/day oral for ~12 weeks to ~26 weeks (± selenium 200 mcg in stacked arms). trial
  • Framing: Discussion ranges only — not advice, not prescriptions, not self-treatment protocols. Hospital antidote mg/kg math is not consumer capsule dosing. forum
  • Mucolytic nebulized (clinical): Label-style 10% or 20% acetylcysteine solutions (e.g. several mL of 20% solution multiple times daily) — clinical handling, not home research-powder nebulizing. trial
  • OCD trial-style: ~1,200–3,000 mg/day oral, commonly ~2,400–3,000 mg split BID/TID over ~10–16 weeks; some arms titrate from 600 mg with weekly doubling; one protocol style used ~2,000 mg/day then optional step to 3,000 mg if non-response after ~8 weeks. trial
  • Skin-picking RCT band: ~1,200–3,000 mg/day (target up to 3,000 in Grant et al. 12-week RCT); open-label and case reports sometimes hold ~2,400 mg. trial
  • Autism adjunct trial span: Roughly ~500–4,200 mg/day across pediatric RCTs lasting ~8–24 weeks; the low-dose (~500 mg) large null trial is cited in community underdosing arguments, not proof that larger amounts would work. trial
  • GlyNAC (Sekhar-style weight-based): ~100 mg/kg/day glycine + ~100 mg/kg/day NAC for multi-week blocks (e.g. ~16 weeks in key older-adult RCT; some arms use matching alanine placebo controls). trial
  • GlyNAC fixed-dose short RCTs: Matched pairs such as 1.2/1.2 g, 2.4/2.4 g, or 3.6/3.6 g/day (total actives ~2.4 / 4.8 / 7.2 g) for ~2 weeks in healthy older adults — safe/tolerated; full-cohort GSH rise not always significant; post-hoc benefit mainly in high-oxidative-stress / low-baseline-GSH subsets. trial
  • Hospital oral APAP protocol (context only): Loading 140 mg/kg, then 70 mg/kg every 4 h × 17 doses (~72 h oral regimen; total ~1,330 mg/kg) — emergency care only. trial
  • Hospital IV APAP protocol (context only): Classic 3-bag ~21 h regimen: 150 mg/kg over 1 h, then 50 mg/kg over 4 h, then 100 mg/kg over 16 h (~300 mg/kg total); newer 2-bag / continuous-infusion options also exist in poison-center labeling updates — not consumer use. trial
  • IV weight caps talk: Some U.S. protocols discuss maximum weight cutoffs (e.g. ~100 kg IV / ~110 kg oral in certain labels) while clinicians often still use actual body weight — overdose-care nuance only. trial
  • GlyNAC mmol framing: Some Examine-style summaries describe ~1.33 mmol/kg/day component framing (equivalent talk around ~100 mg/kg glycine and a higher ~133 mg/kg NAC conversion depending on molar math) — readers should stick to the primary paper’s stated mg/kg. trial

How it may feel 8

  • Early oral experience / separate blood peak: Oral Tmax is often ~1–2 h, a plasma measurement rather than a felt-onset clock. Sulfur taste/smell, mild queasiness, or “empty-stomach burn” can show early in use. trialforum
  • Same day (mucus / hangover lore): Some mucus users notice easier cough same day; hangover/detox feel is highly placebo-confounded. forum
  • Days 1–7: Mucus users sometimes describe thinner sputum first; some reports describe psych/BFRB goals still feeling flat at wellness 600 mg. GI tolerance is an early checkpoint. These are reported experiences, not a universal response timeline. forum
  • Weeks 1–2: Gut-tolerance and airway-comfort check; BFRB dose ramps (e.g. 600 → 1,200 → 1,800–2,400) often sit here with 1–3 week holds per step. forum
  • Weeks 3–6: Common OCD/BFRB/craving reassessment for urge noise vs no-change; some picking/pulling anecdotes claim earlier shifts after dose step-ups (e.g. urge drop within a week of 600 → 1,200). forum
  • Weeks 8–12: Matches many mental-health, BFRB, and addiction trial lengths — usual community “fair trial” before abandoning multi-gram plans. trial
  • Weeks 16–24 (psych adjunct): Schizophrenia negative-symptom and some OCD protocols lean longer; meta-talk argues short 8-week psych windows may under-detect slow effects. trial
  • Months 3–6: Common for fertility (~3 mo continuous 600 mg), respiratory habits, and open-ended GSH/liver routines; long controlled non-clinical data is thinner than short RCTs. trial

Cycles people discuss 10

  • Default pattern: Ongoing daily oral use — not strict peptide-style on/off cycles. forum
  • Seasonal / illness pulses: Higher or steadier dosing around cold season, travel, or acute mucus flares — informal. forum
  • Hangover / event pulses: Single-day or weekend dosing around drinking — not a studied clinical protocol. forum
  • Time off: For GI intolerance, cost, trace-mineral worry, surgery/procedure holds, or to test if benefits stick — no universal washout protocol. forum
  • Restarts: Common after gaps, stress, or flares; less formal cycling than SARMs/secretagogues. forum
  • Psych / BFRB “fair window”: 8–12 weeks mirrors many OCD, skin-picking, trichotillomania, and addiction study durations; some OCD/schizophrenia protocols extend to 16–24+ weeks. trial
  • Fertility block: ~3 months continuous 600 mg/day is the common trial length before reassessing semen parameters; some RCTs ran ~26 weeks on-treatment then treatment-free follow-up. trial
  • Respiratory chronic: Months-long or open-ended daily use in COPD/bronchitis/bronchiectasis culture when tolerated (observational follow-up up to multi-year continuous use appears in literature). trial
  • GlyNAC study blocks: 2-week fixed-dose pilots vs ~12–16 week weight-based older-adult trials — community sometimes copies block length then stops or reduces. trial
  • Long-term evidence gap: BFRB/SUD/psych trials are mostly weeks–months; multi-year psych safety at multi-gram oral doses is thinner than short RCT data. Some forum users report years at 600–1,200 mg with few issues; multi-gram multi-year self-experiments are anecdotes, not trials. trial

Timing 10

  • Split-dose rationale in discussion: Posts describe 2–3× daily oral splits as daily totals climb, citing GI tolerance and multi-hour plasma kinetics. Those are reported rationales, not proof that the plasma clock establishes a dosing schedule or felt-effect coverage. forum
  • GSH lag: Short circulating free NAC vs longer claimed intracellular GSH/redox effects with daily repeats — users judge “feel” days–weeks later. forum
  • Empty stomach vs food: Empty stomach often preferred for absorption lore; with meals preferred when nausea hits — practice not fully standardized. forum
  • Procedure / labs talk: Some consumer monographs discuss pausing before elective surgery or certain blood tests because of clotting-effect lore — not universal medical policy. forum
  • Classic human PK (Olsson et al. style): Terminal half-life ~5.6 h after IV and ~6.3 h after oral for total NAC; oral bioavailability of total NAC ~9% (reduced free NAC even lower, ~4% in same work). trial
  • Other oral half-life figures: ~6–8 h plasma shorthand appears in consumer guides. Papi et al. reported terminal estimates of ~15–19 h after single 600 mg oral tablet doses within a study that also included repeated dosing. Its baseline-corrected assay reduces disulfides; these are not free-NAC-only values, evidence that repeat dosing lengthens half-life, or a duration for felt/GSH effects. trial
  • Cmax timing: Oral peak often ~1–2 h after dose. trial
  • Low oral bioavailability: Single-digit to low-teen percentages are reported depending on the measured free/reduced versus total NAC endpoint. These are not interchangeable assays or a conversion between multi-hundred-mg to multi-gram oral supplement totals and IV clinical loads. trial
  • Activated charcoal timing (overdose care): Charcoal can bind oral NAC; clinical protocols sequence them carefully — not a wellness tip. trial
  • ESRD / kidney impairment PK: Severely reduced clearance (~90% lower clearance vs healthy in one multiple-dose oral study) and much longer half-life (e.g. ~50+ h vs ~4 h control figures in that work) reported in end-stage renal disease — not a casual high-dose population. trial

More on what it is 6

  • Why people use it: Liver/detox and hangover stacks, sticky mucus/COPD, glutathione repletion when plain oral GSH is doubted, and multi-gram OCD/BFRB/craving threads. forum
  • What it is: Acetylated form of the amino acid L-cysteine — long-standing clinical mucolytic and acetaminophen (APAP) overdose antidote; also widely sold as OTC oral capsules, tablets, powder, and effervescent forms. trial
  • Mechanism (simplified): Donates cysteine for intracellular glutathione (GSH) synthesis; modulates cystine–glutamate exchange (system xc−) linked to urge/compulsion lore; splits disulfide bonds in mucus glycoproteins (mucolytic). trial
  • Evidence split: Strongest for APAP overdose + mucolytic/COPD dosing culture; mixed positive and null RCTs for OCD, BFRBs, addiction, schizophrenia adjuncts, and general “detox.” trial
  • Not: Not a peptide, not a cure for OCD/addiction/chronic disease alone, not interchangeable milligram-for-milligram with hospital IV/oral antidote protocols. trial
  • Regulatory note (US talk): FDA treats NAC as excluded from the dietary-supplement definition because it was approved as a drug before supplement marketing (prior drug approval era ~1963). August 2022 final guidance described enforcement discretion for certain NAC products labeled as supplements that would otherwise be lawful supplements; Amazon delist/relist ~2021–2022 still shows up in supply/scare threads. trial

Stacks 11

  • Liver stack: NAC + milk thistle (silymarin); sometimes TUDCA, ALA, choline-type supports, or vitamin C. forum
  • Hangover stack: NAC + electrolytes + B-vitamins + hydration; sometimes milk thistle or DHM — heavily confounded multi-ingredient products. forum
  • Trace-mineral co-stack (community lore): Zinc, copper, selenium, molybdenum multi-minerals because long-term high-dose NAC is accused of chelating/depleting copper/zinc (and molybdenum is sometimes added in sulfur-metabolism lore) — anecdotal, not a settled trial mandate. anecdote
  • BFRB patient-handout co-stack: Multivitamin + minerals + ~500 mg vitamin C co-mentioned with the 600 → 1,200 → 1,800 mg ramp. forum
  • Respiratory stack: Hydration, saline rinse/neb, expectorants, prescribed inhalers — confounded non-drug factors. forum
  • Psych / BFRB adjunct: Logs often add SSRIs/SNRIs, habit-reversal therapy (HRT), inositol, or other supplements — hard to isolate NAC. forum
  • Fertility stack: NAC + selenium, L-carnitine, CoQ10, vitamin E, zinc, folate — common male-infertility forum combos. forum
  • GlyNAC: Glycine + NAC — top glutathione-precursor / aging-redox stack; weight-based study loads (~100 mg/kg each) vs consumer 600/600 starts vs fixed 1.2–3.6 g each short pilots. trial
  • NAC vs oral GSH debate: Many prefer NAC (or liposomal/sublingual GSH) because plain oral GSH is argued to break down poorly; some comparative work favored sublingual GSH over oral GSH and NAC for plasma GSH markers — still contested. trial
  • Antioxidant stack: Vitamin C, selenium, ALA, vitamin E alongside NAC; selenium + NAC appears in older fertility work (~200 mcg Se + 600 mg NAC). trial
  • Avoid unsupervised with nitrates: NAC can potentiate nitroglycerin (more headache, hypotension risk in clinical combo studies). trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 18

  • Mucolytic GI lore: Forums note NAC thins mucus including GI mucus layers; some users link high-dose use to stomach pain or mucosal irritation — mechanism talk is common, controlled long-term gut-mucus trials in healthy supplement users are not the main evidence base. forum
  • Sulfur taste/odor: Rotten-egg smell/taste of product or breath/sweat; some switch brands, effervescent forms, refrigerate, or keep bottles tightly sealed; smell is a poor sole potency test. forum
  • Sulfur-metabolism talk: High-dose users sometimes add molybdenum “to clear sulfur byproducts” — forum lore, not a required co-factor proven in NAC RCTs. anecdote
  • Headache / dizziness: Occasional oral reports; more discussed with IV anaphylactoid-type reactions. Separate mental-effect reports: The sparse-use thread describes less brain fog/noise followed by anhedonia and depression after several consecutive days; another account describes anhedonia within weeks. Anxiety, improvement after stopping and disagreement about perceived prevalence also appear. Co-use, diagnoses and product identity are uncontrolled; these posts establish neither causation nor a preventive schedule. trialforum
  • Trace mineral depletion lore: Long-term users report low copper/zinc (and sometimes iron/selenium) attributed to thiol chelation — add minerals or cycle off is common forum advice; controlled long-term depletion trials are not the main evidence base. anecdote
  • Training-adaptation caution: High-dose antioxidant stacks (including NAC) are debated in sports science for potentially blunting some training signals — community split between recovery use and periodizing off hard training blocks. forum
  • Dose confusion: Do not copy hospital antidote mg/kg schedules or multi-gram psych/SUD doses unsupervised; the pediatric null trich trial reminds readers that adult positive signals do not always transfer. The low-dose autism null trial feeds community underdosing speculation, but does not establish that a higher dose would work. forum
  • GI (most common oral): Nausea, vomiting, diarrhea, heartburn, bloating, gas, abdominal pain — dose-dependent; worse multi-gram or empty stomach. trial
  • Skin: Rash, flushing, urticaria, pruritus — minority; stop-and-reassess if progressive. trial
  • Asthma / bronchospasm: Label and monograph caution, especially inhaled/IV and reactive-airway users; oral flares also reported anecdotally. trial
  • IV anaphylactoid reactions: Flushing, itching, angioedema, bronchospasm, hypotension — more an infusion issue (histamine-type, often non-IgE); asthmatics at higher risk talk; managed by slowing/stopping infusion in clinical settings. trial
  • Clotting / bleeding discourse: NAC may impair platelet aggregation / slow clotting in monographs — caution with bleeding disorders, anticoagulants, and pre-op holds in consumer guides. trial
  • Nitroglycerin / nitrates: Combo can increase headache and symptomatic hypotension; labels and psych education sites flag the interaction. trial
  • Drug / charcoal interactions: Clinical care sequences oral NAC vs activated charcoal carefully in overdose; check clinically relevant meds beyond DIY stacks. trial
  • ESRD / kidney impairment PK: Severely reduced clearance and much longer half-life reported in end-stage renal disease — not a casual high-dose population. trial
  • Massive overdose case lore: Extreme NAC overdoses (e.g. ~100 g scale) linked to hemolysis, thrombocytopenia, renal failure, death in rare reports show that toxicity is not zero. These exceptional cases do not establish a harmless range for capsule misuse. trial
  • Pregnancy / self-treatment: Overdose NAC is used clinically when indicated; elective multi-gram psych self-protocols are a different risk frame — clinical decision territory. trial
  • Disease-claim marketing: Hangover-cure and “cures X disease” labeling has drawn regulatory attention — research/education framing only. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →